Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Acute Toxicity: oral

Currently viewing:

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: OECD, GLP study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1999
Report date:
1999

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
Version / remarks:
This type of study is no longer part of the OECD guidelines for the Testing of Chemicals
GLP compliance:
yes
Test type:
standard acute method

Test material

Constituent 1
Reference substance name:
Azacyclonol
EC Number:
204-092-5
EC Name:
Azacyclonol
Cas Number:
115-46-8
IUPAC Name:
diphenyl(piperidin-4-yl)methanol
Test material form:
solid - liquid: suspension
Details on test material:
- Name of test material (as cited in study report): Azacyclonol-Base
- Physical state: whitish granular powder
- Purity: 98.3 % (w/w)
- Impurities (identity and concentrations): included in the certificate of analysis
- Batch No.: 86000298
- Storage conditions: at +4°C and protected from Iight
- Date of receipt: 31 October 1997
- A certificate of analysis is included in the report.

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Iffa Crédo, Domaine des Oncins, 69210 L’Arbresle, France
- Number and sex: Two males and two females were used for the preliminary test and three groups of five males and/or five females each for the main test.
- Age at initiation of treatment: 6 weeks
- Weight at initiation of treatment: Male: 182 ± 8 g; Female: 149 ± 10 g
- Fasting period before study: Food was withdrawn 18 hours before dosing and redistributed approximately 4 hours after administration of the test substance.
- Housing: housed in polycarbonate cages (48 cm x 27 cm x 20 cm). 4 to 7 animals of the same sex during the acclimatization period and 5 rats of the same sex during the treatment period. Each cage contained dust-free sawdust (SICSA).
- Diet (e.g. ad libitum): controlled pelleted rodent diet (AO4 C, U.A.R.) ad libitum.
- Water (e.g. ad libitum): filtered by a F.G. Millipore membrane (0.22 micron)
- Acclimatization period: 5 days before treatment

ENVIRONMENTAL CONDITIONS
- Temperature: 21 ± 2 ° C
- Relative Humidity: 30 to 70%
- Ventilation: 12 cycles/hour of filtered, non-recycled air
- Light/dark cycle: 12/12 hours



Administration / exposure

Route of administration:
oral: gavage
Vehicle:
other: 0.5% methylcellulose aqueous solution
Details on oral exposure:
VEHICLE
- Concentration in vehicle: Suspension in a 0.5% methylcellulose aqueous solution
- Administration volume: 10 mL/kg
Doses:
Preliminary study: 1000 and 2000 mg/kg
Main study: 750, 1000 and 1300 mg/kg
No. of animals per sex per dose:
Preliminary study: 2 rats/sex/dose
Main study: 5 rats/males/dose and 5 females rats for 1000 mg/kg
Control animals:
other: Historical controls from October 1994 to December 1996.
Details on study design:
- Treatment frequency: Once, a single administration on day 1 (D1)
- Duration of observation period following administration: 15 days
- Frequency of observations and weighing:
= Clinical signs: daily observations
= Body weight (D1, 8, 15)
- Necropsy of survivors performed: yes at D15
Statistics:
The 70 to 95 % confidence interval limits were calculated statistically according to Fieller's method ( 1944).

Results and discussion

Preliminary study:
At the 2000 mg/kg dose-level: animals died on day 1 or 2; sedation or hypoactivity, tremors and piloerection were noted prior to death.
At the 1000 mg/kg dose-level: sedation or hypoactivity, tremors, dyspnoea and piloerection were observed in both animals on days 1 and 2. No mortality occurred. Recovery was complete on day 3.
Effect levelsopen allclose all
Sex:
male
Dose descriptor:
LD50
Effect level:
984 mg/kg bw
Based on:
not specified
Remarks on result:
other: Determination of LD50 with 70% confidence interval limits
Sex:
female
Dose descriptor:
LD50
Effect level:
> 1 000 mg/kg bw
Based on:
not specified
Mortality:
No mortality was recorded among the females (1000 mg/kg).
In males, mortality was 100%, 60% and 0% in the 1300, 1000 and 750 mg/kg dose-groups, respectively. Mortality occurred between day 2 and day 8.
Clinical signs:
other: At 1300 mg/kg dose-level: hypoactivity, piloerection and tremors in all males from day 1. Dyspnoea, sedation and lateral recumbency in one animal prior to death. At 1000 mg/kg dose-level: Sedation or hypoactivity, tremors and piloerection in all animals o
Gross pathology:
No treatment-related changes.

Applicant's summary and conclusion

Interpretation of results:
Toxicity Category IV
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
The LD50 determined experimentally was 984 mg/kg in male. Toxicity was lower in females, concentration level of 1000 mg/kg bw did not induce any adverse effects. According to the 1272/2008 CLP regulation, the substance is classified category 4 for acute oral toxicity.